亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

武漢梓海生物科技有限公司  

醫藥原料,醫藥中間體

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:秦利
  • 電話:027-84767066
  • 郵件:2625799548@qq.com
  • 傳真:027-84767066
  • QQ:2625799548
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 湖北供應枸櫞酸氯米芬
湖北供應枸櫞酸氯米芬
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
庫存 1000kg起訂1kg
品牌 梓海
CAS NO. 50-41-9
分子式 C26H28ClNO C6H8O7
標準 CP /USP
過期 長期有效
更新 2015-06-08 14:32
 
詳細信息

枸櫞酸氯米芬 
中文別名:N,N-二乙基-2-[4-(1,2-二苯基-2-氯乙烯基)苯氧基]乙胺枸櫞酸鹽, 氯芪酚胺枸櫞酸鹽;枸櫞酸氯米芬;舒經酚;克羅米酚;氯芪酚胺, 英文名稱:Clomifene citrate 英文別名:2-[4-(2-Chloro-1,2-diphenylethenyl) phenoxy]-N,N-diethylethanamine citrate; Clomifene;Dyneric;Clomid; 
CAS NO.:50-41-9 分子式:C26H28ClNO C6H8O7 分子量:598.11
性狀:白色或乳白色結晶性粉末。熔點116.5- 118℃,微溶于乙醇、氯仿、水,不溶于**。
標準:CP /USP 
用途:該品為抗雌激素(生育力誘導物),物于功能性子宮出血、多囊卵巢、月經紊亂及藥物引起的閉經等婦科疾病。 


©2025 武漢梓海生物科技有限公司 版權所有   技術支持:化工網   訪問量:9863  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |